Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

@article{Pajic2010TumorinitiatingCA,
  title={Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.},
  author={Marina Pajic and Ariena Kersbergen and Frank N J van Diepen and Anita Pfauth and Jos Jonkers and Piet Borst and Sven Rottenberg},
  journal={Cell cycle},
  year={2010},
  volume={9 18},
  pages={3780-91}
}
Although many breast cancers respond to chemotherapy or hormonal therapy, lack of tumor eradication is a central clinical problem preceding the development of drug resistant tumors. Using the K14cre;Brca1(F5-13/F5-13);p53(F2-10/F2-10) mouse model for hereditary breast cancer, we have previously studied responses of mammary tumors to clinically relevant anti… CONTINUE READING